Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 164

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 164
---
 provide no assurance of the successful and timely development of new products.

    ●
    We must comply with significant government regulations.

29

    ●
    We rely upon patents to protect our technology. We may be unable to protect our intellectual property rights.

    ●
    The price of our common stock may be volatile.

    ●
    The market prices for our common stock may be adversely impacted by future events.

    ●
    A limited public trading market may cause volatility in the price of our common stock.

    ●
    Our Rights Agreement contains anti-takeover provisions that could discourage, delay or prevent a change in control, which may cause our stock price to decline.

You should carefully consider
the risks described below as well as other information provided to you in this document, including information in the section of this
document entitled “Information Regarding Forward Looking Statements.” If any of the following risks actually occur, the Company’s
business, financial condition or results of operations could be materially adversely affected, the value of the Company’s Common
Stock could decline, and you may lose all or part of your investment.

RISKS RELATED TO OUR BUSINESS

There is doubt about our ability to continue
as a going concern.

As of December 31, 2024, the
Company had an accumulated deficit of $163,104,000. Losses have principally occurred as a result of the substantial resources required
for research and development of the Company’s product candidates which included the general and administrative expenses associated
with its organization and product development as well as the lack of sources of revenues until such time as the Company’s products
are commercialized. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the 12
months from the issuance date of these financial statements. These financial statements do not include any adjustments to reflect the
possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result
from the outcome of these uncertainties. Management intends to pursue additional funding and implement its strategic plan to allow the
opportunity for the Company to continue as a going concern, however, there cannot be any assurance that we will be successful in doing
so. The opinion of our independent registered public accounts on our audited financial statements for the year ended December 31, 2024,
contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.

There is no assurance that
we will be successful in raising the additional funds needed to fund our